一週打一次的incretin mimetics+metofrmin，比januvia/actos都好，還可減肥

Once-Weekly Exenatide vs. Sitagliptin or Pioglitazone for Type 2 Diabetes
Long-acting exenatide lowered glycosylated hemoglobin levels more than the other two drugs did.


In patients with type 2 diabetes, incretin mimetic drugs stimulate glucose-related insulin secretion, attenuate glucagon release, and delay gastric emptying. Glucagon-like peptide-1 (GLP-1) receptor agonists such as the currently available formulation of exenatide (Byetta) require once- or twice-daily injections; a once-weekly subcutaneous formulation of exenatide is under FDA review. The oral dipeptidyl peptidase-4 (DPP-4) inhibitor sitagliptin (Januvia) slows the degradation of endogenous GLP-1. Incretin mimetics are alternatives to sulfonylureas or thiazolidinediones when diabetes is not controlled by metformin alone.

With support from the developers of once-weekly exenatide, researchers randomized 491 adults with type 2 diabetes (glycosylated hemoglobin [HbA1c] level, 7.1%–11.0% with stable metformin dosing) to add either exenatide (2 mg weekly) or maximal once-daily oral doses of sitagliptin (100 mg) or pioglitazone (Actos; 45 mg). Each patient also received oral or injected placebo.

After 26 weeks, exenatide lowered the mean HbA1c level significantly more than either sitagliptin or pioglitazone (–1.5% vs. –0.9% and –1.2%). Patients who received exenatide also lost significantly more weight than those who took the other two agents (–2.3 kg vs. –0.8 kg and +2.8 kg). No major hypoglycemic episodes were reported. Nausea and diarrhea were the most common adverse events associated with exenatide and sitagliptin; upper respiratory infection and peripheral edema were the most common adverse events with pioglitazone.

Comment: In an earlier trial (JW Gen Med Jul 13 2010), once-weekly exenatide was superior to daily insulin glargine for short-term glycemic control and weight loss. Long-acting exenatide likely will become an important new option for managing patients with type 2 diabetes.

— Bruce Soloway, MD

Published in Journal Watch General Medicine August 26, 2010

Citation(s):

Bergenstal RM et al. Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): A randomised trial. Lancet 2010 Aug 7; 376:431. (http://dx.doi.org/10.1016/S0140-6736(10)60590-9)

* Medline abstract (Free)

https://docs.google.com/fileview?id=0B278nGJMQBk7YTE2NGY0ZWMtYTI2YS00MDlkLTk4ZmYtZTg1YjYyZjM2MjE3&hl=zh_TW

留言

張貼留言

這個網誌中的熱門文章

即便是用IGRA, 有時也要等大於三個月才能決定TB contact

圖片
接觸TB後，TST大抵上2-12週轉陽，IGRA大抵上6-10週，但IGRA可以長到3個月以上 TB Tests Can Have a Lengthy Window Period Two studies suggest that interferon- release assay conversion sometimes occurs more than 3 months after exposure to active tuberculosis. Increasingly, interferon- release assays (IGRAs) are being used for diagnosing latent tuberculosis (TB). Although the tuberculin skin test (TST) traditionally used for this purpose converts to positive within 2 to 12 weeks after an individual is exposed to someone with active TB, the interval for IGRA conversion has remained unclear. Current guidelines recommend repeating an initially negative IGRA after 6 to 10 weeks, but this recommendation is not based on controlled studies. Two recent investigations address this issue. Anibarro and colleagues conducted a longitudinal prospective analysis among contacts of TB patients in Spain. The 152 contacts received a TST and an IGRA at first visit; for individuals with negative or conflicting results, t
閱讀完整內容

白宮為了掌控醫療費用，傾向大型醫療，個體戶勢必受挫

所以一旦政府介入，中外醫療提供者都傾向大型化…… independent practice -> dreaming 診所評鑑??應該擋住! http://www.medscape.com/viewarticle/727420 Physicians Say White House Should Not Write Off Small Practices August 24, 2010 — In a newly published article, the White House is advising physicians to accept a life in Big Medicine — as a hospital employee or member of a large group practice — in the wake of healthcare reform. Some leaders of organized medicine, however, are objecting to the government message. "We're not ready to write off the small practices," J. Fred Ralston Jr, MD, president of the American College of Physicians, told Medscape Medical News. "We think there needs to be more than one delivery model." "America is not a one-size-fits-all country," added M. Todd Williamson, MD, a neurologist from Lawrenceville, Georgia, and spokesperson for a coalition of medical societies opposed to the new healthcare reform law, now called the Affordable Care Act. Dr. Ralston and Dr.
閱讀完整內容

老美接受LTBI treatment的人，不到一半完治，和duration成正比

This study shows that although acceptance of LTBI treatment is relatively high (83%), the proportion completing is low (47%). When the product of these two proportions is calculated, we see that completion was achieved by only 39% of persons who were offered LTBI treatment. The major risk factor for noncompletion was being prescribed the 9-month INH regimen. As shown in Figure 1, when the proportions completing the three most commonly prescribed regimens are compared, it can be seen that there is an inverse relationship between length of the regimen prescribed and the proportion completing treatment. The increased completion that we observed with the 4-month rifampin regimen is consistent with previous reports.[18–20] It is of interest to note that if completion of the 9-month regimen were defined as completion of at least 6 months of INH, the noncompletion rate of the 9-month regimen, 42.9%, would have been almost identical to that of the 6-month regimen, 44.8%. Thus, prescribing the
閱讀完整內容